(PharmaNewsWire.Com, October 31, 2020 ) The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the growing number of transplant procedures, and technological advancements in the field of transplant diagnostics.
Thermo Fisher Scientific is the top player in the global HLA typing for the transplants market. The company offers various diagnostic imaging modalities and services for transplant diagnostic procedures (includes HLA typing) in the market. To sustain its leadership position and ensure its future growth, the company has been focusing on product launches, agreements, and collaborations.
According to the new market research report by MarketsandMarkets, HLA typing for the transplants market is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%.
The HLA typing for the transplants market, by technology, is segmented into molecular and non-molecular assay technologies. In 2019, the molecular assay technologies segment accounted for the largest share of the HLA typing for the transplants market. The large share of this segment can be attributed to the benefits offered by molecular assays such as low turnaround time, high procedural efficacy, the study of multiple samples, and real-time sample analysis.
The large share of this segment can be attributed to the rapid modernization and automation of diagnostic laboratories, growing number of research & development activities outsourced by pharmaceutical & biotechnology companies to independent reference laboratories, and the growing number of organ transplantation procedures.
Based on end-user, the HLA typing for the transplants market is segmented into independent reference laboratories, hospitals & transplant centers, and research laboratories & academic institutes. In 2019, independent reference laboratories accounted for the largest share of the HLA typing for the transplants market.
North America accounted for the largest share of the HLA typing for transplants market in 2019
North America is a well-established market for medical devices. The presence of a highly developed healthcare system, high adoption of innovative transplant diagnostic technologies (includes HLA typing) among medical professionals, the large volume of organ transplantation procedures performed in the region, and technological advancements in the field of transplant diagnostics are the major factors driving the market in North America.
Some of the players in the HLA typing for transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Luminex (US), Biofortuna (UK), Takara Bio (Japan), Omixon (Hungary)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
